Anebulo Pharmaceuticals

Anebulo Pharmaceuticals is a clinical-stage biotech company developing novel therapeutics to address acute cannabinoid intoxication and substance use disorders. The company's lead candidate, ANEB-001, is a cannabinoid receptor antagonist designed to reverse the effects of cannabis poisoning. Founded in 2019 and based in Austin, Texas, Anebulo is targeting the urgent medical need created by increasing cannabis legalization and related emergency room visits.